CCS Cell Culture Service has signed a general license agreement with Millipore Corporation that allows CCS to create bulk cell amounts from over 250 of EMD Millipore’s assay cell lines, enhancing customers’ drug discovery and high throughput functional screening capabilities.
With this agreement, CCS’s highly flexible service, which meets customers’ scale-up needs, becomes available for EMD Millipore’s well-proven assay cell lines. EMD Millipore owns more than 180 GPCR-expressing cell lines (ChemiScreen, ChemiBrite lines) and 60 ion channel-expressing cell lines (PrecisION lines). From these, CCS can produce custom assay-ready frozen cells or membranes and may even use the cells as a host for transient bulk transfections.
Customers who have already licensed a cell line from EMD Millipore can order reagents prepared from this cell line from CCS without further approval by EMD Millipore. Those who would like to get access to EMD Millipore’s technologies for the first time can license the cell line via CCS in a one-stop-shop.
“Years of experience in frozen cell production makes CCS a reliable outsourcing partner for global pharmaceutical research”, stated Umesh A. Patel, Ph.D., Director, Lead Discovery, EMD Millipore. “Customers relying on our GPCR and Ion Channel cell line products will be provided with a complete solution to support their drug discovery needs.”
“I’m very glad that we can offer our services for EMD Millipore’s cell lines now as well. This makes it very convenient for our customers to obtain high quality cell based reagents for their screening approaches”, said Dr. Oliver Wehmeier, Managing Director and President of CCS.
